Original Research Paper



Anaesthesiology

POSTOPERATIVE EMESIS IN PEDIATRIC PATIENTS: GRANISETRON VS GRANISETRON AND DEXAMETHASONE COMBINATION

Dr.Rashmi Bengali

Asso. Prof. Department of Anaesthesia, Govt Medical college Aurangabad. - Correspondence Author

Dr. Shiksha singh

Senior Resident. Department of Anaesthesia, Govt Medical college Aurangabad.

Granisetron is a potent and highly selective 5-HT-3 receptor antagonist with no affinity for dopaminergic or adrenergic receptors. Its antiemetic efficiency increases when it is used in combination with steroids. 60 patients undergoing for tonsillectomy of ASA 1 and 2, of either sex, of age 6 to 12 yrs were studied for post operative nausea and vomiting. Patients were allocated in two groups of 30 each. Grp A received Inj Granisetron 40µg/Kg while Grp B received combination of Inj Granisetron 40µg/Kg and inj Dexamethasone 150µg/Kg just after induction. Patients were observed for 24 hrs for incidence of vomiting ,retching, need of rescue antiemetic or any other side effect. Complete response was seen in 22(73.4%) patients in Grp A and 29(96.6%) patients in Grp B.

KEYWORDS: Granisetron, Dexamethasone, Tonsillectomy, PONV.

Introduction

Post operative nausea and vomiting (PONV) is the most common distressing and undesirable symptom occurring in 13-42% of all pediatric patients .Severe PONV may be associated with wound dehiscence, pulmonary aspiration of gastric contents, bleeding , dehydration and electrolyte imbalance. Tonsillectomy is a commonly performed pediatric procedure and 70% children experience vomiting in postoperative period leading to delayed hospital discharge and parental dissatisfaction. Combination of antiemetics from different pharmacological classes would provide enhanced efficacy with reduced adverse effects. Granisetron, a selective anatagonist of 5-hydroxy tryptamine type 3(5-HT3) receptor has more potent and longer acting properties than Ondensetron. Dexamethasone has combined anti-inflammatory and antiemetic property hence useful in tonsillectomy.

A study was designed to compare the efficacy of combination of Granisetron and Dexamethasone with Granisetron alone in the prevention of PONV after tonsillectomy in children.

Study design: Prospective, Randomized Double blind clinical trial.

Aims and Objectives

- To study the efficacy of Granisetron in prevention of PONV in children undergoing tonsillectomy under general anaesthesia.
- To study the efficacy of combination of Granisetron and Dexamethasone in prevention of PONV in children undergoing tonsillectomy under general anaesthesia.
- To compare the efficacy of Granisetron alone with the efficacy of combination
- 4) To study the side effects of both the drugs if any.

Material and Methods

After obtaining the approval from institutional ethical committee, 60 patients of age group 6-12yrs of either sex belonging to ASA I and II undergoing elective tonsillectomy were included in the study. While patients with history of allergy to any study drug, patients who have consumed antiemetics, antihistaminics, antipsychotics or terfenedine within 24 hrs before surgery, patients with history of motion sickness, or patients having peritonsillar abscess, patients with indication of recurrent tonsillitis were excluded from the study.

Informed written consent was obtained from the parents of patient. Investigations like Hb%, TLC, DLC, Urine analysis Bleeding time, Clotting Time, Blood Grouping, Blood sugar were noted. After confirming the NBM status, subjects were randomly divided into two groups of 30 each.

Group A: Received IV Granisetron $40\mu g/Kg$ and saline. Group B: Received IV Granisetron $40\mu g/Kg$ and IV Dexamethasone 0.15 mg/Kg (max upto 8mg). These drugs were administered IV over 30sec. after induction of anaesthesia.

Both the groups were premedicated with Inj Midazolam 0.03mg/kg IV and Inj Pentazocine 0.3mg/Kg IV. Preoxygenation was done with 100% O2 for 3 min. After induction with Inj Thiopentone sodium 4-5 mg/Kg. intubation was done under the effect of Inj Succinylcholine 2mg/Kg IV with appropriate sized PVC cuffed or uncuffed endotracheal tube. Anaesthesia was maintained with O₂/N₂O and Halothane and Inj. Atracurium as muscle relaxant. Monitoring was done for Heart rate, NIBP,ECG and SpO, throughout the procedure. Reversal was done with Inj.Neostigmine 0.05mg/Kg and Inj.Glycopyrrolate 0.008mg/Kg IV. Patients were extubated after return of all reflexes. Postoperatively all episodes of nausea and vomiting were recorded. Inj Metaclopropamide 0.15mg/kg IV was used as a rescue antiemetic if two episodes of vomiting occur within 24 hrs after anaesthesia. Patients were enquired about side effects like headache, lightheadedness, drowsiness or diarrhea. Postoperative Pain was treated with per rectal suppository of Acitaminophen 10-15 mg/Kg.

Statistics

Patient demographic data, duration of fasting, duration of anaesthesia and surgery were analysed by unpaired Student's t test. The frequency of postoperative vomiting, need for rescue antiemetics and incidence of adverse effects were analysed using Fishers exact test and Chi square test. P value of $<\!0.05$ was deemed statistically significant.

Results

Both groups were compared for mean age, sex, weight and were found to be nonsignificant (p=>0.05)

Table 1: Comparison between duration of anaesthesia and surgery.

Duration	Group A	Group B	P value
Mean duration of	76.8(SD-7.5)	80(SD-6)	0.072(NS)
anaesthesia(min)			
Mean duration of	61.9(SD-	64.73(SD-	0.135(NS)
surgery(min)	8.28)	6.02)	

Both parameters were found to be nonsignificant.

Table 2: Comparison of incidence of vomiting and retching between two groups.

Drug	Children having vomiting	having	Children having vomiting or retching
Group A Granisetron 40μg/kg	7(23.3%)	1(3.3%)	8(26.6%)
Group B Granisetron 40μg/kg +Dexamethasone 150 μg/kg	1(3.3%)	0	1(3.3%)
P value	0.026(S)	0.50(NS)	0.022(S)

Incidence of vomiting between two groups was compared with

Fisher's exact test. Incidence of early as well as late vomiting was significantly reduced statistically when combination of drugs was used. (p<0.05).

Incidence of retching was not significant (p>0.05) However combined incidence of vomiting and retching when compared with two groups was found to be statistically significant. (p < 0.05).

Children having two or more episodes of vomiting were given Inj.Metoclopramide 0.15mg/kg IV as rescue antiemetic.No patient in Grp B and only one patient in Grp A required rescue antiemetic. P value obtained was 0.5 which was statistically nonsignificant.

Table 3: Side effects.

Groups	Headache	Diarrhoea	Drowsiness	Others
Group A	3(10%)	2(6.6%)	0	1
(Granisetron) n=30				
Group B	4(13.3%)	1(3.3%)	0	1
(Granisetron				
+Dexamethasone)				
n=30				

Incidence of side effects among the two groups was compared using the Fisher's exact test. There was no statistically significant difference in either grp (p>0.05).

With the change in emphasis from inpatient to outpatient care and possibility of delayed discharge or unexpected hospital admission ,PONV has been called the Big little problem PONV affects the economics of medical care, as well as the degree of patient's satisfaction, comfort and quality of life. PONV has gained importance in prevention and treatment because of increase in ambulatory and office based anaesthesia, newer techniques, antiemetics, use of multimodal therapy etc.

The present study compares the efficacy of combination of Granisetron and Dexamethasone with Granisetron alone in the prevention of postoperative nausea and vomiting after tonsillectomy in children. The incidence in preschool children is 20% while in school going age group it is 34-50% with rising trends in girls. As age itself is independent risk factor for PONV, prophylactic antiemetic is advocated in pediatric age group.^{2,3}Obesity poses a special problem as adipose tissue acts as a reservoir for anaesthetic agents and may show increased incidence in recovery period4.

Duration of anaesthesia is an important parameter for nausea. The rise in incidence from 17.5% to 46% is seen when duration is more than one hour. Although full stomach patients are likely to vomit in postoperative period, increased duration of fasting also increases the incidence.6

In our study we selected pediatric patients undergoing tonsillectomy. PONV is one of the most common and significant complication in tonsillectomy with or without adenoidectomy demanding delayed discharge, incidence being upto 70%. It is possible that surgical technique may influence the PONV, but there is no evidence to support this hypothesis. The anaesthetic technique has an important bearing over degree of PONV. Among the intravenous agents Propofol has least incidence of PONV compared to Ketamine. Inhalational agents like Sevoflurane or Isoflurane show minimal degree of PONV. Anticholinesterase like Neostigmine can cause vomiting due to muscarinic effect by increasing the gastric motility. All these agents demand prophylactic use of antiemetics.

In our study we use Granisetron and Dexamethasone as antie metics. 5 -HT- 3 receptor antagonists are devoid of any side effects or drug interactions, hence their discovery is a major advance for treatment of PONV. The peak plasma concentration of IV Granisetron is 30 min.with elimination half life of 6.3 hrs. Fujii et al in a study concluded that Granisetron given in a dose of 40µg/kg is adequate to prevent PONV.8

In our study 8 (26.6%) children who received Granisetron alone had one or more episodes of vomiting and retching requiring rescue antiemetic in first 24 hrs postoperatively. It indicates that 73.4 % children had complete response with Granisetron prophylaxis.

Dexamethasone in a dose of 0.15mg/Kg is an effective antiemetic with plasma half life of 4hrs.Combination of Granisetron with Dexame thasone has been used with more efficiency as steroids may reduce the levels of 5-Hydroxytryptophan, prevent release of serotonin in gut and potentiate action of antiemetics by sensitizing pharmacological receptors 9. In our study 96.6% children had complete response when combination was used as only one patient had vomiting in first 24 hrs.

The common side effects seen with Granisetron are headache, vomiting, diarrhoea and constipation 10.Long term use of corticost eroids is associated with adrenal suppression or avascular necrosis of hip, but single dose is considered safe. However in our study only few patients had mild headache which was relieved without any medicines. No other complications were seen in either group.

Conclusion

Combination of Granisetronn and Dexamethasone significantly lowers the incidence of postoperative emesis. However the incidence of need of rescue antiemetics or any other side effects is similar when Granisetron is used alone or in combination.

References

- Fisher Dennis M:The big little problem of postoperative nausea and vomiting;Do we
- know the answer yet/. Anaesthesiology: Vol 87(6), December 1997; pg 1271-73
 Rose J.B., Watcha M.F.: Postoperative nausea and vomiting in paediatric patients. Br J Anaesth 1999:83;104-17
- EberhartL.H.Jetal: Applicability of risk scores for postoperative nausea and vomiting in adultstopaediatric patients.Br. J. Anaesth 2004;93:386-92
- Gan TongJet al.: A randomized double blind study of Granisetron plus dexamethasone versus Ondansetron plus Dexamethasone to prevent postoperative nausea and vomiting in patients undergoing abdominal hysterectomy. Anaesth Analg. 2005;101:13
 Bellville J.W;Brass I D J;Howlands W S:Postoperative nausea and vomiting IV, Factors
- related to Postoperative nausea and vomiting. Anaesthesiology 1960;21:186-93
- WatchaMehernoorF,White Paul F: Review article Postoperative nausea and vomiting.Anaesthesiology,1992;77:162-184
- Matti Aapro: Granisetron An update on its clinical use in the management of nausea and vomiting. The Oncologists 2004;9:673-686.
- Fujii Yoshitaka ,Tanaka Hiroyoshi et al :Effective dose of Granisetron for preventing postoperative emesis in children .Can J Anaesth 1996;43:7;660-4. Henzi Iris et al Dexamethasone for prevention of postoperative nausea and vomiting:a
- quantitative systemic review. Anaesth Analge 2000;90:186-94
- Matti Aapro : Granisetron , an update on its clinical use in the management of nausea and vomiting . The oncologist 2004;9:673-86.